Intravitreal implant could bring significant cost savings to NHS EnglandA study has revealed that a budgetary saving per treated patient with the fluocinolone acetonide implant (Iluvien) versus ranibizumab (Lucentis) could lead to a significant cost-saving to NHS England.
Data demonstrate real-world benefits of fluocinolone acetonide implantReal-world data on a fluocinolone acetonide intravitreal implant show sustained benefits of switching to the treatment in pseudophakic eyes that are insufficiently responsive to other therapies.
Why 'the more the merrier' doesn't apply to glaucoma monitoringThough ocular hypertension may be the only modifiable risk factor for glaucoma, the second-leading cause of sight loss in the United Kingdom, monitoring for ocular hypertension more than twice a year is not efficient, researchers said.
NICE gives aflibercept provisional green light for DMENICE has released a draft decision recognizing the benefits of aflibercept solution for injection for the majority of patients with visual impairment caused by DME.
UK's NICE clears path of Iluvien for patient availabilityThe United Kingdom's National Institute for Health and Care Excellence (NICE) published its final guidance for a sustained-release intravitreal implant (Iluvien), clearing the path to patient availability through the National Health Service (NHS).
ThromboGenics acquires rights to develop DME drugThromboGenics NV has entered into a collaboration and license agreement with Bicycle Therapeutics to develop and commercialize drugs inhibiting a specific target for the treatment of diabetic macular edema (DME).